2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 391-392
Optimal dose for haploidentical transplant<br />Better characterizing products for retroviral vector mutations<br />Association of CD39 expression on CAR T-cells with oxidative stress/lipid peroxidation<br />Characterizing CAR T-cells based on LymphoMAP archetype.<br />Optimizing conditions for potency of CAR NK Cells<br />Efficient base gene editing for SCD using the Prodigy
Technology and Procedures, Assays, Molecular Testing, Gene Editing, Treatment Considerations, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Biological Processes, Immune Mechanism, Metabolism, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Patient-Reported Outcomes, Study Population, Human
PAPER

436 Rapcabtagene autoleucel manufactured using the T-Charge™ platform preserves T cell stemness and overcomes immunosuppressive tumor microenvironments in R/R DLBCL

Jeanne Whalen, Pere Barba, MD, PhD2, Carlos Solano, MD, PhD3, Ian W. Flinn, MD, PhD4, Ulrich Jaeger, MD5, Peter Riedell, MD6, Javier Briones, MD, PhD7, Aravind Ramakrishnan, MD8, Michael Green, PhD9, David Demanse10, Pushpa Jayaraman, PhD11, Avishek Pal, MS12, Pedro Marques Ramos, PhD13, Aisha Masood, MD14, Elena Orlando, PhD15, Louise Treanor16
1 Biomedical Research, Novartis Pharmaceuticals Corporation, Cambridge, United States
2 Department of Hematology, Hospital Universitari Vall d’Hebron, Barcelona, Spain
3 Hematology Service, Hospital Clínico Universitario-INCLIVA de Valencia, Valencia, Spain
4 Tennessee Oncology / Greco-Hainsworth Tennessee Oncology Centers for Research; former Director of Blood Cancer, Sarah Cannon Research Institute, Nashville, United States
5 Clinical Division of Hematology and Hemostaseology, Medical University of Vienna / AKH Vienna, Vienna, Austria
6 Department of Medicine, Hematology/Oncology, University of Chicago, Chicago, United States
7 Clinical Hematology Unit, Hospital de la Santa Creu i Sant Pau; Autonomous University of Barcelona, Barcelona, Spain
8 Sarah Cannon Transplant and Cellular Therapy Program at South Austin Medical Center, Austin, United States
9 The University of Texas MD Anderson Cancer Center, Houston, United States
10 Novartis Pharma AG, Basel, Switzerland
11 Biomedical Research, Novartis Pharmaceuticals Corporation, Cambridge, United States
12 Novartis Pharma AG, Basel, Switzerland
13 Novartis Pharma AG, Basel, Switzerland
14 Novartis Pharmaceuticals Corporation, East Hanover, United States
15 Novartis Pharmaceuticals Corporation, East Hanover, United States
16 Biomedical Research, Novartis Pharmaceuticals Corporation, Cambridge, United States

Background: CAR-T cells have revolutionized treatment for patients with r/r DLBCL; however, durable remission is achieved in <50% of patients.  The T-Charge™ manufacturing platform reduces manufacturing time to less than two days while preserving the immunophenotypic characteristics and stemness of the incoming apheresis in the final product (Dickenson et al, 2023). This approach enables in vivo expansion leading to an increase in efficacy in comparison to first generation CAR-Ts, achieving an overall response rate of 86%, a CRR of 69% and a PFS of 55% @ 12 months in 3L+ R/R DLBCL (Barba et al, ASH 2026). Tumor subtypes defined by distinct microenvironmental characteristics, known as archetypes, are associated with differential responses to CAR-T (Li et al, 2025). We characterized both CAR-T manufacturing features and the baseline tumor microenvironment (TME) in patients treated with Rapcabtagene autoleucel to assess the biological attributes that may contribute to enhanced clinical efficacy including overcoming an adverse TME. Here we report analysis from 3L + DLBCL patient samples from the PhII study (NCT03960840) using single-cell RNA sequencing.

Methods:  Paired apheresis and CAR-T product samples were analyzed by single-cell RNA sequencing and pre-treatment tumor biopsies by bulk RNA-sequencing.Tumor samples were classified using the LymphoMAP framework, which defines three major lymphoma archetypes: FMAC (low T-cell infiltration and enrichment of cancer-associated fibroblasts and tumor-associated macrophages); LN (lymph node architectural cell types and enrichment of naïve and memory T cells); and TEX (activated macrophages and exhausted CD8+ T cells) (Li et al. Cancer Cell 2025).

Results: Analysis of paired apheresis and rapcabtagene autoleucel final product samples showed that the stemness present in the apheresis was maintained in the final product and in fact rapcabtagene autoleucel had higher expression of a stemness-associated transcriptional program than traditional CAR-T products (Ramalho et al., 2002; Haradhvala et al., 2022). This increase in stemness was observed regardless of the LymphoMAP archetype of the corresponding tumor. The final product also showed increased immune activation and interferon-gamma gene signatures, consistent with an activated T-cell phenotype. Together, these findings suggest that the T-Charge manufacturing process produces transcriptionally distinct CAR-T cells that combine an activated phenotype with preservation of less differentiated cellular states, which may contribute to the distinct biological profile of rapcabtagene autoleucel.

We then evaluated whether baseline tumor archetype was associated with response to rapcabtagene autoleucel. LymphoMAP archetype assignment was performed on screening tumor biopsies from 33 patients with 3L+ R/R DLBCL. Tumors were classified as LN in 26% of patients (7/33), FMAC in 41% (14/33), and TEX in 32% (11/33). As expected, based on prior reports, patients with LN tumors had a high best overall response rate (ORR; CR+PR) of 100% (7/7). Notably, patients with TEX tumors also had the best ORR of 100% (11/11) after rapcabtagene autoleucel treatment. At Month 6, complete response rates were also similar in LN and TEX tumors, with 67% complete responses observed in both groups. These results suggest that rapcabtagene autoleucel may drive meaningful responses in TEX tumors, a LymphoMAP subtype typically associated with more challenging CAR-T outcomes.

Conclusions: rapcabtagene autoleucel manufactured using the T-Charge™ platform preserves favorable T-cell biological characteristics, including activation and stemness-associated transcriptional programs. The findings presented herein suggest that these features enable rapcabtagene autoleucel to be active across challenging lymphoma microenvironmental archetypes, including TEX tumors, a subgroup traditionally associated with exhausted T cells and poor CAR-T outcomes. Prior LymphoMAP-based analyses have reported lower best ORR of 30% to 70% with CAR-T therapy in this subgroup (Li et al., 2025). Even though the sample size is limited, this suggests that rapcabtagene autoleucel may overcome key biological barriers associated with T-cell exhaustion within the tumor microenvironment.

Jeanne Whalen: Novartis Pharmaceuticals Corporation - Current equity holder in publicly-traded company; Novartis Pharmaceuticals Corporation - Current Employment